Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2023;34(4):547-9
Article Links
Hydroxychloroquine-Induced Stevens–Johnson Syndrome in the Patient with Systemic Lupus Erythematosus: A Case Report in Kurdish Region - Iraq
Niaz Al-Barzinji1, Aryan Mohamadfatih Jalal2
Authors Information

1College Of Medicine, Hawler Medical University, Erbil, Iraq

2Department of Rheumatology, Kurdistan Board for Medical Specialties, Erbil, Iraq

Jalal AM

Keywords: systemic lupus erythematosus, hydroxychloroquine, Stevens-Johnson Syndrome
References
  1. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers 2016;2:1603.
  2. Wong KC, Kennedy PJ, Lee S. Clinical manifestations, and outcomes in 17 cases of Stevens- Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol 1999;40:131-4.
  3. Wolkenstein P, Revuz J. Drug-induced severe skin reactions. Incidence, management, and prevention. Drug Saf 1995;13:56-68.
  4. Sekula P, Dunant A, Mockenhaut M, Naldi L, Bouwes Bavinick JN, Halevy S, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013;133:1197-204.
  5. Choon S, Lai N. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary care hospital in Johor, Malaysia. Indian J Dermatol 2012;78(6):734-9.
  6. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5(39).
  7. Thong BY. Stevens-Johnson syndrome/toxic epidermal necrolysis: An Asia-Pacific perspective. Asia Pac Allergy 2013;3(4):215-23.
  8. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020;75:491–786.
  9. Davoodi L, Jafarpour H, Kazeminejad A, Soleymani E, Akbari Z, Razavi A. Hydroxychloroquine-induced Stevens–Johnson syndrome in COVID-19: a rare case report. Oxf Med Case Reports 2020 Jun;2020(6):omaa042.
  10. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;36:e212–3.
  11. Volpe A, Marchetta A, Caramaschi P, Biasi D, Bambara LM, Arcaro G. Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol 2008;27:537.
  12. Leckie M, Rees R. Stevens–Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. Rheumatology 2002;41:473-4.
  13. Bergin C, Philbin M, Gilvarry P, O'Connor M, King F, Adams R, et al. Interim guidance for the use of antiviral therapy in the clinical management of acute respiratory infection with SARS-CoV-2 (COVID-19), [v2. 0]. Health Service Executive, 2020.
  14. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:1-12.
  15. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020;369:m1432.
  16. Callaly E, FitzGerald O, Rogers S. Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis. Clin Exp Dermatol 2008;33:572–4.